{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T09:01:22Z","timestamp":1765530082954,"version":"3.48.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,12]]},"DOI":"10.7759\/cureus.99023","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:57:43Z","timestamp":1765529863000},"source":"Crossref","is-referenced-by-count":0,"title":["Expert Opinion of Empagliflozin Positioning in the Current Type 2 Diabetes Mellitus (T2DM) Landscape in Indian Patients"],"prefix":"10.7759","author":[{"given":"Bipin","family":"Sethi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwani","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arundhati","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoj","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilakshi","family":"Deka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navneet","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chinmoy","family":"Mazumder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ipshita","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishal","family":"Gala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer","family":"Muchhala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akanksha","family":"Sonkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S002","article-title":"Diagnosis and classification of diabetes: standards of care in diabetes-2025","volume":"48","year":"2025","unstructured":"Diagnosis and classification of diabetes. standards of care in diabetes-2025. Diabetes Care. 2025, 48:S27-49. 10.2337\/dc25-S002","journal-title":"Diabetes Care"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/ejcn.2017.40","article-title":"Prevalence of type 2 diabetes and its complications in India and economic costs to the nation","volume":"71","author":"Pradeepa R","year":"2017","unstructured":"Pradeepa R, Mohan V. Prevalence of type 2 diabetes and its complications in India and economic costs to the nation. Eur J Clin Nutr. 2017, 71:816-24. 10.1038\/ejcn.2017.40","journal-title":"Eur J Clin Nutr"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202100275","article-title":"Emerging targets in type 2 diabetes and diabetic complications","volume":"8","author":"Demir S","year":"2021","unstructured":"Demir S, Nawroth PP, Herzig S, Ekim \u00dcst\u00fcnel B. Emerging targets in type 2 diabetes and diabetic complications. Adv Sci (Weinh). 2021, 8:e2100275. 10.1002\/advs.202100275","journal-title":"Adv Sci (Weinh)"},{"key":"ref4","article-title":"","year":"2025","unstructured":"IDF Diabetes Atlas. International Diabetes Federation, Brussels, Belgium; 2025. https.\/\/diabetesatlas.org\/media\/uploads\/sites\/3\/2025\/04\/IDF_Atlas_11th_Edition_2025.pdf."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(18)30387-5","article-title":"The increasing burden of diabetes and variations among the states of India: the Global Burden of Disease Study 1990-2016","volume":"6","year":"2018","unstructured":"The increasing burden of diabetes and variations among the states of India. the Global Burden of Disease Study 1990-2016. Lancet Glob Health. 2018, 6:e1352-62. 10.1016\/S2214-109X(18)30387-5","journal-title":"Lancet Glob Health"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(15)00326-5","article-title":"Type 2 diabetes in migrant south Asians: mechanisms, mitigation, and management","volume":"3","author":"Sattar N","year":"2015","unstructured":"Sattar N, Gill JM. Type 2 diabetes in migrant south Asians: mechanisms, mitigation, and management. Lancet Diabetes Endocrinol. 2015, 3:1004-16. 10.1016\/S2213-8587(15)00326-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30174-2","article-title":"Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR-INDIAB population-based cross-sectional study","volume":"5","author":"Anjana RM","year":"2017","unstructured":"Anjana RM, Deepa M, Pradeepa R, et al.. Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR-INDIAB population-based cross-sectional study. Lancet Diabetes Endocrinol. 2017, 5:585-96. 10.1016\/S2213-8587(17)30174-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025","volume":"48","year":"2025","unstructured":"Pharmacologic approaches to glycemic treatment. standards of care in diabetes-2025. Diabetes Care. 2025, 48:S181-206. 10.2337\/dc25-S009","journal-title":"Diabetes Care"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2021.04.007","article-title":"Klotho: a possible mechanism of action of SGLT2 inhibitors preventing episodes of acute kidney injury and cardiorenal complications of diabetes","volume":"26","author":"Kale A","year":"2021","unstructured":"Kale A, Sankrityayan H, Anders HJ, Bhanudas Gaikwad A. Klotho: a possible mechanism of action of SGLT2 inhibitors preventing episodes of acute kidney injury and cardiorenal complications of diabetes. Drug Discov Today. 2021, 26:1963-71. 10.1016\/j.drudis.2021.04.007","journal-title":"Drug Discov Today"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0002772021","article-title":"SGLT2 inhibitors: physiology and pharmacology","volume":"2","author":"Wright EM","year":"2021","unstructured":"Wright EM. SGLT2 inhibitors: physiology and pharmacology. Kidney360. 2021, 2:2027-37. 10.34067\/KID.0002772021","journal-title":"Kidney360"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10123294","article-title":"New insights into the use of empagliflozin-a comprehensive review","volume":"10","author":"Forycka J","year":"2022","unstructured":"Forycka J, Hajdys J, Krzemi\u0144ska J, et al.. New insights into the use of empagliflozin-a comprehensive review. Biomedicines. 2022, 10:3294. 10.3390\/biomedicines10123294","journal-title":"Biomedicines"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-24-01926","article-title":"Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2024 clinical practice guideline","volume":"178","author":"Madero M","year":"2025","unstructured":"Madero M, Levin A, Ahmed SB, et al.. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2024 clinical practice guideline. Ann Intern Med. 2025, 178:705-13. 10.7326\/ANNALS-24-01926","journal-title":"Ann Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"79","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al.. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol. 2022, 79:e263-e421. 10.1016\/j.jacc.2021.12.012","journal-title":"J Am Coll Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16162965","article-title":"SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects","volume":"16","author":"Tentolouris A","year":"2019","unstructured":"Tentolouris A, Vlachakis P, Tzeravini E, Eleftheriadou I, Tentolouris N. SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects. Int J Environ Res Public Health. 2019, 16:2965. 10.3390\/ijerph16162965","journal-title":"Int J Environ Res Public Health"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington WG","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, et al.. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023, 388:117-27. 10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker SD","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al.. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021, 385:1451-61. 10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"key":"ref17","article-title":"Empagliflozin as add-on to metformin for 24 weeks improves glycemic control in patients with type 2 diabetes (T2DM)","volume":"62","author":"H\u00e4ring HU","year":"2013","unstructured":"H\u00e4ring HU, Merk L, Seewaldt-Becker E, Weimer M, Meinicke T. Empagliflozin as add-on to metformin for 24 weeks improves glycemic control in patients with type 2 diabetes (T2DM). Diabetes. 2013, 62:A282.","journal-title":"Diabetes"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2673","article-title":"Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial","volume":"36","author":"H\u00e4ring HU","year":"2013","unstructured":"H\u00e4ring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Woerle HJ, Broedl UC. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013, 36:3396-404. 10.2337\/dc12-2673","journal-title":"Diabetes Care"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12188","article-title":"Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial","volume":"16","author":"Kovacs CS","year":"2014","unstructured":"Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, Broedl UC. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2014, 16:147-58. 10.1111\/dom.12188","journal-title":"Diabetes Obes Metab"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70084-6","article-title":"Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"1","author":"Roden M","year":"2013","unstructured":"Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle HJ, Broedl UC. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013, 1:208-19. 10.1016\/S2213-8587(13)70084-6","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12503","article-title":"Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial","volume":"17","author":"Rosenstock J","year":"2015","unstructured":"Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2015, 17:936-48. 10.1111\/dom.12503","journal-title":"Diabetes Obes Metab"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2020.12.008","article-title":"Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: results from the CREDENCE trial","volume":"233","author":"Sarraju A","year":"2021","unstructured":"Sarraju A, Li J, Cannon CP, et al.. Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: results from the CREDENCE trial. Am Heart J. 2021, 233:141-8. 10.1016\/j.ahj.2020.12.008","journal-title":"Am Heart J"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2021.06.017","article-title":"Effects of dapagliflozin in patients with kidney disease, with and without heart\u00a0failure","volume":"9","author":"McMurray JJ","year":"2021","unstructured":"McMurray JJ, Wheeler DC, Stef\u00e1nsson BV, et al.. Effects of dapagliflozin in patients with kidney disease, with and without heart\u00a0failure. JACC Heart Fail. 2021, 9:807-20. 10.1016\/j.jchf.2021.06.017","journal-title":"JACC Heart Fail"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.057812","article-title":"Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved trial","volume":"145","author":"Butler J","year":"2022","unstructured":"Butler J, Filippatos G, Jamal Siddiqi T, et al.. Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved trial. Circulation. 2022, 145:184-93. 10.1161\/CIRCULATIONAHA.121.057812","journal-title":"Circulation"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.IJEM_517_16","article-title":"Long-term efficacy and safety of empagliflozin monotherapy in drug-na\u00efve patients with type 2 diabetes in Indian subgroup: results from a 76-week extension trial of phase III, double-blind, randomized study","volume":"21","author":"Gupta S","year":"2017","unstructured":"Gupta S, Shaikh S, Joshi P, Bhure S, Suvarna V. Long-term efficacy and safety of empagliflozin monotherapy in drug-na\u00efve patients with type 2 diabetes in Indian subgroup: results from a 76-week extension trial of phase III, double-blind, randomized study. Indian J Endocrinol Metab. 2017, 21:286-92. 10.4103\/ijem.IJEM_517_16","journal-title":"Indian J Endocrinol Metab"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","unstructured":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022, 102.S1-S127. 10.1016\/j.kint.2022.06.008","journal-title":"Kidney Int"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-1646","article-title":"Empagliflozin reduces liver fat in individuals with and without diabetes","volume":"47","author":"Abdelgani S","year":"2024","unstructured":"Abdelgani S, Khattab A, Adams J, et al.. Empagliflozin reduces liver fat in individuals with and without diabetes. Diabetes Care. 2024, 47:668-75. 10.2337\/dc23-1646","journal-title":"Diabetes Care"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial)","volume":"41","author":"Kuchay MS","year":"2018","unstructured":"Kuchay MS, Krishan S, Mishra SK, et al.. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial). Diabetes Care. 2018, 41:1801-8. 10.2337\/dc18-0165","journal-title":"Diabetes Care"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa321","article-title":"Cardiovascular benefit of empagliflozin across the spectrum of cardiovascular risk factor control in the EMPA-REG OUTCOME trial","volume":"105","author":"Inzucchi SE","year":"2020","unstructured":"Inzucchi SE, Khunti K, Fitchett DH, et al.. Cardiovascular benefit of empagliflozin across the spectrum of cardiovascular risk factor control in the EMPA-REG OUTCOME trial. J Clin Endocrinol Metab. 2020, 105:3025-35. 10.1210\/clinem\/dgaa321","journal-title":"J Clin Endocrinol Metab"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker TA","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al.. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019, 393:31-9. 10.1016\/S0140-6736(18)32590-X","journal-title":"Lancet"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.ijem_377_23","article-title":"SGLT2 inhibitors: paradigm shift from diabetes care to metabolic care-an Indian perspective","volume":"28","author":"Kumar KM","year":"2024","unstructured":"Kumar KM, Unnikrishnan AG, Jariwala P, et al.. SGLT2 inhibitors: paradigm shift from diabetes care to metabolic care-an Indian perspective. Indian J Endocrinol Metab. 2024, 28:11-8. 10.4103\/ijem.ijem_377_23","journal-title":"Indian J Endocrinol Metab"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer M","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al.. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020, 383:1413-24. 10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney DZ","year":"2014","unstructured":"Cherney DZ, Perkins BA, Soleymanlou N, et al.. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014, 129:587-97. 10.1161\/CIRCULATIONAHA.113.005081","journal-title":"Circulation"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409183","article-title":"Long-term effects of empagliflozin in patients with chronic kidney disease","volume":"392","author":"Herrington WG","year":"2025","unstructured":"Herrington WG, Staplin N, Agrawal N, et al.. Long-term effects of empagliflozin in patients with chronic kidney disease. N Engl J Med. 2025, 392:777-87. 10.1056\/NEJMoa2409183","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies MJ","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al.. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022, 45:2753-86. 10.2337\/dci22-0034","journal-title":"Diabetes Care"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2014.01.007","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis","volume":"8","author":"Baker WL","year":"2014","unstructured":"Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014, 8:262-75.e9. 10.1016\/j.jash.2014.01.007","journal-title":"J Am Soc Hypertens"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray JJ","year":"2019","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, et al.. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019, 381:1995-2008. 10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.039177","article-title":"Empagliflozin and the risk of heart failure hospitalization in routine clinical care","volume":"139","author":"Patorno E","year":"2019","unstructured":"Patorno E, Pawar A, Franklin JM, et al.. Empagliflozin and the risk of heart failure hospitalization in routine clinical care. Circulation. 2019, 139:2822-30. 10.1161\/CIRCULATIONAHA.118.039177","journal-title":"Circulation"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0126-x","article-title":"Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor","volume":"53","author":"Scheen AJ","year":"2014","unstructured":"Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2014, 53:213-25. 10.1007\/s40262-013-0126-x","journal-title":"Clin Pharmacokinet"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors AA","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR, et al.. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022, 28:568-74. 10.1038\/s41591-021-01659-1","journal-title":"Nat Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink HJ","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020, 383:1436-46. 10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial","volume":"140","author":"Verma S","year":"2019","unstructured":"Verma S, Mazer CD, Yan AT, et al.. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial. Circulation. 2019, 140:1693-702. 10.1161\/CIRCULATIONAHA.119.042375","journal-title":"Circulation"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl S","year":"2020","unstructured":"Kahl S, Gancheva S, Stra\u00dfburger K, et al.. Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial. Diabetes Care. 2020, 43:298-305. 10.2337\/dc19-0641","journal-title":"Diabetes Care"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-025-01882-8","article-title":"The effect of empagliflozin on non-alcoholic fatty liver disease-related parameters in patients with type 2 diabetes mellitus: a randomized controlled trial","volume":"25","author":"Shojaei F","year":"2025","unstructured":"Shojaei F, Erfanifar A, Kalbasi S, Nikpour S, Gachkar L. The effect of empagliflozin on non-alcoholic fatty liver disease-related parameters in patients with type 2 diabetes mellitus: a randomized controlled trial. BMC Endocr Disord. 2025, 25:52. 10.1186\/s12902-025-01882-8","journal-title":"BMC Endocr Disord"},{"key":"ref46","doi-asserted-by":"crossref","DOI":"10.1186\/s43162-020-00013-0","article-title":"Influence of sodium glucose co-transporter 2 inhibitors on fatty liver index parameters in type 2 diabetes mellitus","volume":"32","author":"Gameil MA","year":"2020","unstructured":"Gameil MA, Abdelgawad MS, Bahgat MH, Elsebaie AH, Marzouk RE. Influence of sodium glucose co-transporter 2 inhibitors on fatty liver index parameters in type 2 diabetes mellitus. Egypt J Intern Med. 2020, 32:","journal-title":"Egypt J Intern Med"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.1909","article-title":"SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria","volume":"35","author":"Chino Y","year":"2014","unstructured":"Chino Y, Samukawa Y, Sakai S, Nakai Y, Yamaguchi J, Nakanishi T, Tamai I. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos. 2014, 35:391-404. 10.1002\/bdd.1909","journal-title":"Biopharm Drug Dispos"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/428401-expert-opinion-of-empagliflozin-positioning-in-the-current-type-2-diabetes-mellitus-t2dm-landscape-in-indian-patients","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:57:44Z","timestamp":1765529864000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/428401-expert-opinion-of-empagliflozin-positioning-in-the-current-type-2-diabetes-mellitus-t2dm-landscape-in-indian-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":47,"URL":"https:\/\/doi.org\/10.7759\/cureus.99023","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,12]]}}}